A Phase 4 interventional study of OnabotulinumtoxinA and SKINVIVE in Jawline and Neck Appearance, sponsored by AbbVie. Recruiting at 2 sites in Canada. Open to participants aged 22 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by AbbVie · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to evaluate overall participant satisfaction with the jawline and neck.
Participants will receive select Juvéderm products and onabotulinumtoxinA in the jaw area and neck per eligibility criteria.
The study will measure changes in psychological function, satisfaction with lower face and jawline and skin appearance. Participants will attend visits during the study at a clinical site. The effects of the treatment will be checked by medical assessments, vital signs, physical examinations, checking for side effects, and completing questionnaires.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the study will receive the products in the jaw area, chin, and neck.
Drug: OnabotulinumtoxinA · Device: SKINVIVE · Device: VOLUX · Device: VOLUMA
Injection
Injection
Injection
Injection
Percentage of Participants With Response of Satisfied or Very Satisfied on Appearance of Neck and Lower Face Questionnaire (ANLFQ): Satisfaction Follow-Up
The ANLFQ is a 5-point scale that assesses participant satisfaction. Response options range from Very satisfied to Very dissatisfied.
Time frame: Day 104
Change From Baseline in Participant's Rasch-transformed Score of the FACE-Q Psychological Function
The FACE-Q Psychological Function scale assesses the psychological impact of facial appearance. The Rasch-transformed summary score ranges from worst to best.
Time frame: Up to approximately 104 days
Change From Baseline in Participant's Rasch-transformed Score of the FACE-Q Satisfaction With Lower Face and Jawline
FACE-Q Satisfaction assesses participant satisfaction with the appearance of their lower face and jawline. The Rasch-transformed summary score ranges from worst to best.
Time frame: Up to approximately 104 days
Change From Baseline in Participant's Rasch-transformed Score of the SKIN-Q - Skin Looks
SKIN-Q - Skin Looks assesses participant's satisfaction with how their skin looks. Rasch transformed scores ranges from worst to best.
Time frame: Up to approximately 104 days
Change From Baseline in Participant's Allergan Facial Confidence Scale (AFCS) - Confidence (Treatment Area) Total Score
AFCS - Confidence (Treatment Area) is a questionnaire that assesses the participant's confidence in the appearance of the treatment area. 4-point response option ranges from Very Confident to Not at all confident.
Time frame: Up to approximately 104 days
Percentage of Participants With Response of Improved or Much Improved on Investigator Global Aesthetic Improvement Scale (GAIS)
GAIS is a clinician-rated 5-point scale that assesses of overall aesthetic improvement compared to baseline. Scores range from "Much improved" to "Much worse".
Time frame: Up to approximately 104 days
Percentage of Participants With Response of Satisfied or Very Satisfied (or Agree or Definitely Agree) on Allergan Facial Satisfaction Scale (AFSS) - Natural Look and Feel
AFSS assesses participant satisfaction. Scores range from "Very satisfied" to" Very dissatisfied".
Time frame: Up to approximately 104 days
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan
Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A